Alvotech (NASDAQ:ALVO) Shares Break Below Two Hundred Day Moving Average – Time to Sell?

Shares of Alvotech (NASDAQ:ALVO) crossed below its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $4.20 and traded as low as $4.13. Alvotech shares last traded at $4.19, with a volume of 2,091,332 shares trading hands.

Key Alvotech News

These are some of the ALVO news items that stood out recently:

• Positive Sentiment: Alvotech forecast 2026 revenue of $650 million–$700 million, broadly around or above the $652.5 million consensus at the midpoint, and EBITDA of $180 million–$220 million. Management said it expects the fourth quarter to be the strongest in company history. Article: Alvotech targets $650M-$700M revenue and $180M-$220M EBITDA
• Neutral Sentiment: The earnings call highlighted growth opportunities alongside business risks; the available article summary did not specify further details. Article: Alvotech Earnings Call Highlights Growth and Risks
• Negative Sentiment: Q3 revenue of $111.6 million fell short of the $125.2 million analyst estimate. Alvotech posted a loss of $0.03 per share; while that beat one reported consensus estimate of a $0.04 loss, it missed Zacks’ estimate of a $0.01 loss. The revenue miss and mixed earnings comparisons could pressure the shares. Article: Alvotech Reports Q3 Loss, Lags Revenue Estimates

Analysts Set New Price Targets

Several equities research analysts have commented on the company. Weiss Ratings raised Alvotech from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, November 4th. Zacks Research downgraded Alvotech from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 20th. Bank of America initiated coverage on Alvotech in a report on Monday, August 24th. They set a “buy” rating and a $7.00 price target for the company. Barclays raised Alvotech from an “underweight” rating to an “overweight” rating and lifted their price target for the stock from $4.00 to $8.00 in a research report on Wednesday, September 16th. Finally, Wall Street Zen cut shares of Alvotech from a “hold” rating to a “sell” rating in a research note on Saturday, November 7th. Five analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Alvotech currently has a consensus rating of “Hold” and a consensus target price of $8.40.

Alvotech Price Performance

The company has a market cap of $1.26 billion, a P/E ratio of -5.11 and a beta of 0.24. The company’s 50-day moving average is $5.23 and its two-hundred day moving average is $4.20.

Alvotech (NASDAQ:ALVO) last released its quarterly earnings data on Wednesday, November 11th. The company reported ($0.03) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.03). The business had revenue of $111.60 million during the quarter, compared to the consensus estimate of $123.45 million. Equities research analysts anticipate that Alvotech will post -0.01 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Ulland Investment Advisors LLC lifted its holdings in shares of Alvotech by 5.0% during the 3rd quarter. Ulland Investment Advisors LLC now owns 115,000 shares of the company’s stock valued at $667,000 after buying an additional 5,500 shares during the period. ProShare Advisors LLC bought a new stake in shares of Alvotech in the third quarter worth $68,000. Commonwealth Equity Services LLC bought a new stake in shares of Alvotech in the third quarter worth $69,000. China Universal Asset Management Co. Ltd. increased its position in Alvotech by 24.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 61,712 shares of the company’s stock valued at $365,000 after acquiring an additional 12,049 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in Alvotech during the third quarter valued at $100,000.

Alvotech Company Profile

Alvotech is a biopharmaceutical company based in Reykjavik, Iceland, focused on developing and manufacturing biosimilars—medicines designed to be highly similar to existing biologic drugs. Its work includes biosimilars for conditions in areas such as immunology and oncology. Founded in 2013 by entrepreneur Robert Wessman, the company operates an integrated development and manufacturing platform in Iceland. Alvotech works with commercial partners to seek regulatory approval for and distribute its products in markets including the United States and Europe.